Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Bitwarden Recognized as a Leading High Performer in the G2 Enterprise Grid® Report for Password Managers
Exclusive-Russian hackers seek war crimes evidence, Ukraine cyber chief says
NTT Supports Guam Network Infrastructure Rebuild in Wake of Typhoon Mawar
Phenom and Pontoon Partner to Deliver Supercharged Talent Experiences to Global Organizations with AI and Automation
Top Ethanol Maker Says States Should Embrace Carbon Pipelines
French Fund Rule Puts $7.6 Billion of Oil, Gas Assets at Risk
These Stocks Are Moving the Most Today: Micron, Peloton, Workday, Nike, CarMax, and More
Elon Musk's X adds to fog of war at outset of Israel-Hamas conflict